



---

an Open Access Journal by MDPI


---

Impact Factor 3.9

CiteScore 6.8

Indexed in PubMed

# Biomedicines



[mdpi.com/  
journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



# Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, biosimilar, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, biosimilars, and nano-biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

## Editor-in-Chief

Prof. Dr. Felipe Fregni

---

## Section Editors-in-Chief

Dr. Veronique Baud  
Dr. Timo Gaber  
Dr. Bernard Lebleu  
Prof. Dr. Jun Lu  
Dr. Bruno Meloni  
Prof. Dr. Stephen Riordan  
Prof. Dr. Paul Rösch

---

## Aims

*Biomedicines* publishes high-quality papers that address the challenges in bringing biological agents or novel targeted strategies through identification, development, and, ultimately, to clinical use. Therefore, laboratory medicine research, translation medical research, comprehensive preclinical studies, and most clinical studies focused on development and early phase clinical trials are all within the scope of the journal.

---

## Scope

- Pathogenesis and mechanisms of diseases;
- Cardiovascular diseases;
- Biomaterial in biomedical research;
- Novel targets in various therapeutic areas: cardiovascular, vascular, hematology, oncology, neurology, orthopedics, dermatology, ophthalmology;
- Biomarker discovery and early diagnosis research;
- Drug discovery and development, pharmacotherapy;
- Basic and clinical pharmacology;
- Biopharmaceutical biomedicine: biologics and biosimilars;
- Nanobiotechnological advances in biomedicine: nanomedicine, nanoscaffold implants (synthetic vascular graft), biosensors, bioimaging, gene therapy, vaccine, cell therapy, and tissue engineering;
- Neurobiology and clinical neuroscience;
- Neuromodulation.

---

## Author Benefits

### Open Access

Unlimited and free access for readers

### No Copyright Constraints

Retain copyright of your work and free use of your article

### Thorough Peer-Review

### No Space Constraints, No Extra Space or Color Charges

No restriction on the maximum length of the papers, number of figures, or use of colors

### Journal Rank

JCR - Q1 (Pharmacology and Pharmacy) /  
CiteScore - Q1 (Medicine (miscellaneous))

### Coverage by Leading Indexing Services

Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases

### Rapid Publication

A first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025)

MDPI is a member of, or collaborates with, the following organizations

CASPA



STM<sup>1</sup>



SPARC\*  
Europe



DOAJ



ORCID

**Affiliated Society:**

Society for Regenerative Medicine (Russian Federation) (RPO)



**Editorial Office**

biomedicines@mdpi.com

MDPI

Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

[mdpi.com](http://mdpi.com)

March 2026

